Humanized antibodies that recognize beta amyloid peptide

• US 7,790,856 B2
• Filed: 09/12/2006
• Issued: 09/07/2010
• Est. Priority Date: 04/07/1998
• Status: Expired due to Fees

• Current Assignee: Janssen Alzheimer Immunotherapy (Johnson & Johnson), Wyeth LLC (Pfizer Inc.)
• Original Assignee: Janssen Alzheimer Immunotherapy (Johnson & Johnson)
• Inventors: Schenk, Dale B.
• Primary Examiner(s): Helms; Larry R.
• Assistant Examiner(s): Natarajan; Meera
• Application Number:
  US11/520,438
• Publication Number:
  US 20070154480A1
• Time in Patent Office: 1,456 Days
• Field of Search: None
• US Class Current: 530/387.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/77 Internalization into the cell
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: C07K 2318/10 Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes

Abstract

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.

Claims

1. A humanized antibody, or fragment thereof, comprising a humanized light chain comprising three light chain complementarily determining regions (CDRs) from the mouse monoclonal antibody 10D5 and a light chain variable region framework sequence from a human immunoglobulin light chain;

and a humanized heavy chain comprising three heavy chain CDRs from the mouse monoclonal antibody 10D5 and a heavy chain variable region framework sequence from a human immunoglobulin heavy chain;

wherein the light chain CDRs have the following amino acid sequences;

2. An antibody fragment obtainable by enzymatic cleavage of the humanized antibody of claim 1.

3. An Fab or F(ab′

)₂ fragment of the humanized antibody of claim 1.

4. The F(ab′

)₂ fragment of claim 3.

5. The Fab fragment of claim 3.

6. The humanized antibody or fragment of any one of claims 1-5, which is a single chain antibody.

7. The humanized antibody or fragment of any one of claims 1-5 that is an IgG1 immunoglobulin isotype.

8. The humanized antibody or fragment of any one of claims 1-5, wherein the antibody or fragment thereof is produced in a host cell selected from the group consisting of a myeloma cell and a chinese hamster ovary (CHO) cell.

9. A chimeric antibody or antigen binding fragment thereof, comprising a light chain comprising a variable region sequence of residues 1-112 of SEQ ID NO:

14 and a human constant region, and a heavy chain comprising a heavy chain variable region of residues 1-123 of SEQ ID NO;

16 and a human constant region.